Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review.

Autor:	Palmieri C; Interdisciplinary Department of Medicine, Hygiene Unit, University of Bari Aldo Moro, Bari, Italy., Moscara L; Interdisciplinary Department of Medicine, Hygiene Unit, University of Bari Aldo Moro, Bari, Italy., Tafuri S; Interdisciplinary Department of Medicine, Hygiene Unit, University of Bari Aldo Moro, Bari, Italy., Stefanizzi P; Interdisciplinary Department of Medicine, Hygiene Unit, University of Bari Aldo Moro, Bari, Italy.
Jazyk:	angličtina
Zdroj:	Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2396220. Date of Electronic Publication: 2024 Sep 12.
DOI:	10.1080/21645515.2024.2396220
Abstrakt:	Two vaccines are available to prevent serogroup B meningococcal disease, i.e. the four-component meningococcal serogroup B vaccine (4CMenB) and the bivalent-factor-H-binding-protein meningococcal serogroup B vaccine (MenB-fHbp). Currently, 4CMenB is offered as part of routine infant immunization schedules. Available immunogenicity data showed a progressive decline in protective serum bactericidal antibodies (SBA) titers, with a re-enhancement following a booster dose during infancy. Responses did not seem to be long-lasting and vaccinated individuals might be at risk of meningococcal diseases duriṇg adolescence. Only one study evaluated the possibility to administer a single booster dose to immunocompetent adolescents who received a primary series during infancy. Despite a high proportion of enrollees achieving protective SBA levels 28 days post-booster, titers tended to decrease 1 year after. Immunocompetent adolescents who received a primary series and a booster during the first two years of life might rather benefit from re-vaccination against MenB; current evidence does not support the possibility of a booster.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu